Sulfate is the active ingredient in amikacin drug formulations. it is an aminoglycoside antibiotic.
Treatment of serious infections caused by susceptible gramnegative bacteria.
Treatment of infections caused by susceptible strains of Pseudomonas aeruginosa, Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae, Enterobacter species), and other gramnegative organisms.
Treatment of serious infections when other antibiotics are ineffective or contraindicated.
Macmika 100mg Inj 2ml (Amikacin) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing the formation of functional proteins, ultimately leading to bacterial cell death.
Store amikacin at room temperature, protected from light and moisture. Do not freeze. Discard any unused portion after the expiration date.
Dosage is determined by the physician based on the severity of the infection, patient's weight, and kidney function.
Amikacin is usually administered intravenously or intramuscularly.
The duration of treatment varies depending on the infection and patient response.
Nephrotoxicity (kidney damage)
Ototoxicity (hearing loss, balance problems)
Nausea
Vomiting
Diarrhea
Rash
Hypersensitivity reactions (allergic reactions)
Neurotoxicity (muscle weakness, paralysis)
Consult your doctor. Alcohol can exacerbate some side effects.
May cause dizziness or drowsiness. Avoid driving or operating machinery until you know how this medication affects you.
Use only if the potential benefit outweighs the risk to the fetus or infant. Consult your doctor.
Dosage adjustments are necessary. Consult your doctor.
Risk of nephrotoxicity is increased in patients with impaired kidney function. Dosage adjustments or close monitoring are usually required.
Generally well-tolerated by the liver, but liver function tests may be monitored in patients with pre-existing liver disease.
Physician's Desk Reference (PDR)
Micromedex
Package insert provided with amikacin medication
